Regen BioPharma Inc financial data

Symbol
RGBP, RGBPP on OTC
Location
La Mesa, CA
Fiscal year end
30 September
Latest financial report
10-Q - Q4 2025 - 13 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.3% % 23%
Debt-to-equity -104% % -0.46%
Return On Equity 13% %
Return On Assets -787% % -26%
Operating Margin -309% % 34%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 108,054,704 shares
Common Stock, Shares, Outstanding 108,054,704 shares 401%
Entity Public Float $1,054,545 USD 0%
Common Stock, Value, Issued $10,806 USD 401%
Weighted Average Number of Shares Outstanding, Basic 99,609,650 shares 2323%
Weighted Average Number of Shares Outstanding, Diluted 99,609,650 shares 2323%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $126,560 USD -18%
Revenue from Contract with Customer, Excluding Assessed Tax $236,561 USD 0%
Research and Development Expense $210,000 USD
General and Administrative Expense $293,721 USD 391%
Costs and Expenses $654,749 USD -29%
Operating Income (Loss) $828,786 USD -133%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $1,726,971 USD -66%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $1,726,971 USD -67%
Earnings Per Share, Basic 0.07 USD/shares 92%
Earnings Per Share, Diluted 0.07 USD/shares 92%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $4,578 USD 3291%
Accounts Receivable, after Allowance for Credit Loss, Current $232,298 USD 90%
Assets, Current $237,076 USD 36%
Assets $237,076 USD 24%
Accounts Payable, Current $11,024 USD -69%
Accrued Liabilities, Current $1,852,221 USD 8.5%
Liabilities, Current $6,810,073 USD 16%
Liabilities $6,810,073 USD 16%
Accumulated Other Comprehensive Income (Loss), Net of Tax $222,580 USD -8.7%
Retained Earnings (Accumulated Deficit) $22,659,473 USD -8.2%
Stockholders' Equity Attributable to Parent $6,572,997 USD -16%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $5,175,963 USD -5%
Liabilities and Equity $237,076 USD 24%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $197,941 USD -198%
Net Cash Provided by (Used in) Financing Activities $132,964 USD 102%
Common Stock, Shares Authorized 5,800,000,000 shares 0%
Common Stock, Shares, Issued 108,054,704 shares 401%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $64,977 USD -11084%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $61,849 USD 8838%
Deferred Tax Assets, Valuation Allowance $4,758,405 USD
Deferred Tax Assets, Gross $4,758,405 USD
Deferred Tax Assets, Operating Loss Carryforwards $4,758,405 USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 800,000,000 shares 0%
Additional Paid in Capital $16,297,234 USD 5.4%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Interest Expense $63,967 USD -29%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%